Who Exports Nifedipine from India — 331 Suppliers Behind a $30.1M Market
India's nifedipine export market is supplied by 331 active exporters who collectively shipped $30.1M across 2,751 shipments. CIPLA LIMITED leads with a 17.2% market share, followed by ALKEM LABORATORIES LIMITED and TORRENT PHARMACEUTICALS LTD. The top 5 suppliers together control 52.7% of total export value, reflecting a moderately competitive market structure.
Top Nifedipine Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading nifedipine exporter from India, holding a 17.2% share of the $30.1M market across 2,751 shipments from 331 exporters. The top 5 suppliers — CIPLA LIMITED, ALKEM LABORATORIES LIMITED, TORRENT PHARMACEUTICALS LTD, J B CHEMICALS AND PHARMACEUTICALS LIMITED, ZYDUS LIFESCIENCES LIMITED — collectively control 52.7% of total export value, indicating a moderately concentrated market. Individual shares are: CIPLA LIMITED (17.2%), ALKEM LABORATORIES LIMITED (12.0%), TORRENT PHARMACEUTICALS LTD (11.4%), J B CHEMICALS AND PHARMACEUTICALS LIMITED (7.9%), ZYDUS LIFESCIENCES LIMITED (4.2%).
Top Nifedipine Exporters from India
Ranked by export value · 331 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED NIFEDIPINE EXTENDED-RELEASE TABLETS 30MGCIPALAT RETARD TAB [31PMS - NIFEDIPINE ER 60 MG TABLET ( INV. | $5.2M | 6 | 17.2% |
| 2 | ALKEM LABORATORIES LIMITED PHARMACEUTICAL PRODUCTS NIFEDIPINE ER TAPHARMACEUTICAL PRODUCTS:NIFEDIPINE ER TANIFEDIPINE EXTENDED - RELEASE TABLETS | $3.6M | 2 | 12.0% |
| 3 | TORRENT PHARMACEUTICALS LTD CALCIGARD RETARD TABLET (NIFEDIPINE 20MGCALCIGARD RETARD TABLET NOS SIZE 2X5X10 TABLETSCALCIGARD RETARD TABLET(NIFEDIPINE 20MG | $3.4M | 9 | 11.4% |
| 4 | J B CHEMICALS AND PHARMACEUTICALS LIMITED NIFEDIPINE EXTENDED-RELEASE TABLETS 30MGNIFEDIPINE RETARD 20CIPALAT RETARD TAB [31 | $2.4M | 13 | 7.9% |
| 5 | ZYDUS LIFESCIENCES LIMITED NIFEDIPINE EXTENDED-RELEASE TABLETS 30MGNIFEDIPINE RETARD 20FINIDIP TABLETS(NIFEDIPINE EXTE | $1.3M | 10 | 4.2% |
| 6 | J B CHEMICALS PHARMACEUTICALS LIMITED NIFEDIPINE EXTENDED-RELEASE TABLETS 30MGNIFEDIPINE RETARD 20CIPALAT RETARD TAB [31 | $1.1M | 9 | 3.6% |
| 7 | LINCOLN PHARMACEUTICALS LTD NIFEDIPINE RETARD 20CALCIGARD RETARD TABLET (NIFEDIPINE 20MGDEPIN E RETARD 20MG TABLETS 10X10 T | $995.2K | 8 | 3.3% |
| 8 | MARKSANS PHARMA LIMITED | $949.0K | 1 | 3.2% |
| 9 | UMEDICA LABORATORIES PRIVATE LIMITED NIFEDIPINE RETARD 20NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTENIFEDIPINE SUSTAINED RELEASE TABLETS (NE | $867.8K | 4 | 2.9% |
| 10 | TORRENT PHARMACEUTICALS LIMITED CALCIGARD RETARD TABLET (NIFEDIPINE 20MGCALCIGARD RETARD TABLET NOS SIZE 2X5X10 TABLETSCALCIGARD RETARD TABLET(NIFEDIPINE 20MG | $678.0K | 7 | 2.3% |
| 11 | MEDWISE OVERSEAS PRIVATE LIMITED NIFEDIPINE EXTENDED-RELEASE TABLETS 30MGCIPALAT RETARD TAB [31NIFIDIWISE 20(NIFEDIPINE EXTENDED-RELEAS | $646.9K | 3 | 2.1% |
| 12 | MEDREICH LIMITED NIFEDIPINA GENERIS 30MG TABLETSNIFEDIPINA GENERIS 60MG TABLETS | $500.6K | 2 | 1.7% |
| 13 | INNOVA CAPTAB LIMITED CALCIGARD RETARD TABLET (NIFEDIPINE 20MGDEPIN E RETARD 20MG TABLETS 10X10 TNEFIN 20ER - NIFEDIPINE EXTENDED RELEASETABLETS USP 20MG | $381.6K | 3 | 1.3% |
| 14 | BELCO PHARMA NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTE | $366.1K | 2 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Nifedipine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla has received FDA approvals for various drugs, including Esomeprazole Magne |
| ALKEM LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Alkem received FDA approval for Azilsartan Medoxomil and Chlorthalidone Tablets |
| TORRENT PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Torrent received FDA approval for Penciclovir Cream, 1% on August 7, 2023. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | Multiple | Zydus received FDA approval for Indomethacin Suppositories USP, 50 mg on August |
| LINCOLN PHARMACEUTICALS LTD | Not Listed | Yes | Yes | Not Applicable | Lincoln Pharmaceuticals received EU GMP certification for its Khatraj facility i |
| MARKSANS PHARMA LIMITED | Approved | Yes | Yes | Multiple | Marksans Pharma has received FDA approvals for various drugs; specific details a |
| UMEDICA LABORATORIES PRIVATE LIMITED | Approved | Yes | Yes | Multiple | Umedica has received FDA approvals for various drugs; specific details are avail |
| MEDREICH LIMITED | Approved | Yes | Yes | Multiple | Medreich has received FDA approvals for various drugs; specific details are avai |
TransData Nexus reviewed the regulatory standing of 8 leading Nifedipine exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Nifedipine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of Active Pharmaceutical Ingredients (APIs). The city's pharmaceutical sector is bolstered by a robust infrastructure and a skilled workforce, making it a hub for API manufacturing. Companies like Shilpa Medicare Ltd., which commenced operations in 1987 in Raichur, Karnataka, have expanded their reach to Hyderabad, contributing to the city's prominence in bulk drug production. Shilpa Medicare is known for manufacturing Nifedipine APIs, underscoring Hyderabad's role in the supply chain of this essential medication.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. This region hosts major companies such as Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited, both headquartered in Ahmedabad. Zydus Lifesciences, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company engaged in the manufacturing of generic drugs. Torrent Pharmaceuticals, established in 1959, operates in more than 40 countries and is active in various therapeutic areas. These companies are instrumental in producing and exporting Nifedipine formulations, leveraging the region's advanced manufacturing facilities and regulatory compliance.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a crucial export gateway for pharmaceuticals. Mumbai, being the financial capital of India, hosts the headquarters of Cipla Limited, a leading pharmaceutical company specializing in generic and specialty pharmaceuticals. Cipla's strategic location facilitates efficient distribution and export of Nifedipine products to international markets, including the United States, Zimbabwe, and Canada, which are among the top destinations for Indian Nifedipine exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives and supportive government policies. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions. While specific data on Nifedipine production in this cluster is limited, the region's overall contribution to India's pharmaceutical output is significant, supporting the broader supply chain.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers, particularly those in Hyderabad and Ahmedabad-Vadodara, to ensure consistent quality of Nifedipine APIs and formulations.
- Leverage Export Hubs: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline the export process and reduce lead times.
- Monitor Regulatory Changes: Stay informed about policy shifts in tax incentive zones like Baddi-Nalagarh to capitalize on cost-saving opportunities and maintain compliance.
By strategically sourcing from these diverse pharmaceutical clusters, TransData Nexus can enhance the resilience and efficiency of its Nifedipine supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Nifedipine exporters from India
Torrent Pharmaceuticals Limited — Torrent Pharma to acquire controlling stake in J.B. Chemicals & Pharmaceuticals
Torrent Pharmaceuticals Limited announced definitive agreements to acquire a 46.39% equity stake in J.B. Chemicals & Pharmaceuticals from KKR at an equity valuation of INR 25,689 crores, followed by a merger of the two entities. This strategic move aims to strengthen Torrent's presence in the Indian pharmaceutical market and expand its product portfolio. - IMPACT: The acquisition is expected to enhance Torrent's Nifedipine production capacity and export capabilities.
Impact: The acquisition is expected to enhance Torrent's Nifedipine production capacity and export capabilities.
Torrent Pharmaceuticals Limited — CCI approves Torrent's acquisition of J.B. Chemicals with modifications
The Competition Commission of India approved the proposed acquisition of J.B. Chemicals & Pharmaceuticals by Torrent Pharmaceuticals, subject to compliance with voluntary modifications offered by the parties. This approval facilitates the consolidation of the two companies, enhancing their market presence. - IMPACT: Regulatory approval paves the way for increased Nifedipine export volumes through combined resources.
Impact: Regulatory approval paves the way for increased Nifedipine export volumes through combined resources.
Alkem Laboratories Limited — Alkem joins race to acquire J.B. Chemicals as Torrent pauses talks
Alkem Laboratories entered discussions to acquire J.B. Chemicals & Pharmaceuticals after Torrent Pharmaceuticals withdrew from negotiations over valuation issues. This move indicates Alkem's intent to expand its market share and product offerings. - IMPACT: Potential acquisition could bolster Alkem's Nifedipine production and export capacity.
Impact: Potential acquisition could bolster Alkem's Nifedipine production and export capacity.
Common Questions — Nifedipine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which nifedipine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 123 recorded shipments worth $5.2M. ALKEM LABORATORIES LIMITED (85 shipments) and TORRENT PHARMACEUTICALS LTD (95 shipments) are also established high-volume exporters.
Q How many nifedipine manufacturers are there in India?
India has 331 active nifedipine exporters with a combined export market of $30.1M across 2,751 shipments to 117 countries. The top 5 suppliers hold 52.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for nifedipine from India?
Average FOB unit price: $8.26 per unit, ranging from $0.00 to $2821.89. Average shipment value: $10.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 331 verified Indian exporters of Nifedipine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,751 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 117 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,751 Verified Shipments
331 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists